血液系统恶性肿瘤患者的戊型肝炎负担:欧洲回顾性队列研究
这项欧洲11中心回顾性队列研究纳入50例RNA阳性、临床显性戊型肝炎的血液系统恶性肿瘤患者,发现戊型肝炎与死亡和肝相关疾病相关,血源性传播 contributes to burden,利巴韦林应早期启用而减少免疫抑制治疗需谨慎。
要点
- 50例血液系统恶性肿瘤合并显性戊型肝炎患者中,持续戊型肝炎期间死亡8例(16%)。
- 戊型肝炎进展为慢性肝炎17例(34%),alloHSCT者10例(47.6%),iNHL者6例(50%)。
- 利巴韦林治疗24例(48%),HEV清除率79.2%,早期启用与较低死亡率相关(p=0.037)。
核心结论
- 戊型肝炎与血液系统恶性肿瘤患者的死亡和肝相关疾病相关,血源性传播 contributes to burden。
- 作者认为利巴韦林应早期启用,而减少免疫抑制治疗需谨慎。
研究设计与样本
- 欧洲11中心回顾性多中心队列研究,纳入2014年4月至2017年3月间50例血液系统恶性肿瘤且RNA阳性、临床显性戊型肝炎患者。
- 主要终点为HEV相关死亡率,次要终点为HEV相关肝病发病率。
主要发现
- 最常见基础血液肿瘤为侵袭性非霍奇金淋巴瘤(NHL)34%、惰性NHL(iNHL)24%和急性白血病36%。
- 21例(42%)接受过异基因造血干细胞移植(alloHSCT);持续戊型肝炎期间死亡8例(16%),包括1例iNHL和1例alloHSCT后>100天且完全缓解者。
- 死亡与男性(p=0.040)、肝硬化(p=0.006)和alloHSCT(p=0.056)相关。
- 血源性传播5例(10%),其中2例与肝相关死亡相关;戊型肝炎进展为慢性肝炎17例(34%),alloHSCT者10例(47.6%),iNHL者6例(50%)。
- 戊型肝炎相关急性或慢加急性肝衰竭4例(8%),死亡率75%;利巴韦林治疗24例(48%),HEV清除率79.2%。
关键数值与推荐
- 利巴韦林在诊断戊型肝炎后<24周启用与较低死亡率相关(p=0.037),<12周启用与较低慢性化率趋势相关(p=0.407)。
- 减少免疫抑制治疗与2例(28.6%)患者死亡相关。
- 暴露于含利妥昔单抗方案的患者中,戊型肝炎进展为慢性肝炎5例(45.5%);干细胞移植受者中10例(47.6%)。
临床怎么用
- 作者认为利巴韦林应早期启用,减少免疫抑制治疗需谨慎。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The burden of hepatitis E virus (HEV) infection among patients with haematological malignancy has only been scarcely reported. Therefore, we aimed to describe this burden in patients with haematological malignancies, including those receiving allogeneic haematopoietic stem cell transplantation. METHODS: We conducted a retrospective, multicentre cohort study across 11 European centres and collected clinical characteristics of 50 patients with haematological malignancy and RNA-positive, clinically overt hepatitis E between April 2014 and March 2017. The primary endpoint was HEV-associated mortality; the secondary endpoint was HEV-associated liver-related morbidity. RESULTS: The most frequent underlying haematological malignancies were aggressive non-Hodgkin lymphoma (NHL) (34%), indolent NHL (iNHL) (24%), and acute leukaemia (36%). Twenty-one (42%) patients had received allogeneic haematopoietic stem cell transplantation (alloHSCT). Death with ongoing hepatitis E occurred in 8 (16%) patients, including 1 patient with iNHL and 1 patient >100 days after alloHSCT in complete remission, and was associated with male sex (p = 0.040), cirrhosis (p = 0.006) and alloHSCT (p = 0.056). Blood-borne transmission of hepatitis E was demonstrated in 5 (10%) patients, and associated with liver-related mortality in 2 patients. Hepatitis E progressed to chronic hepatitis in 17 (34%) patients overall, and in 10 (47.6%) and 6 (50%) alloHSCT and iNHL patients, respectively. Hepatitis E was associated with acute or acute-on-chronic liver failure in 4 (8%) patients with 75% mortality. Ribavirin was administered to 24 (48%) patients, with an HEV clearance rate of 79.2%. Ribavirin treatment was associated with lower mortality (p = 0.037) and by trend with lower rates of chronicity (p = 0.407) when initiated <24 and <12 weeks after diagnosis of hepatitis E, respectively. Immunosuppressive treatment reductions were associated with mortality in 2 patients (28.6%). CONCLUSION: Hepatitis E is associated with mortality and liver-related morbidity in patients with haematological malignancy. Blood-borne transmission contributes to the burden. Ribavirin should be initiated early, whereas reduction of immunosuppressive treatment requires caution. LAY SUMMARY: Little is known about the burden of hepatitis E among patients with haematological malignancy. We conducted a retrospective European cohort study among 50 patients with haematological malignancy, including haematopoietic stem cell transplant recipients, with clinically significant HEV infection and found that hepatitis E is associated with hepatic and extrahepatic mortality, including among patients with indolent disease or among stem cell transplant recipients in complete remission. Hepatitis E virus infection evolved to chronic hepatitis in 5 (45.5%) patients exposed to a rituximab-containing regimen and 10 (47.6%) stem cell transplant recipients. Reducing immunosuppressive therapy because of hepatitis E was associated with mortality, while early ribavirin treatment was safe and effective.
引用
- von Felden J, Alric L, Pischke S, et al. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. J Hepatol. 2019. PMID: 31108159. doi:10.1016/j.jhep.2019.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。